OXFORD BIOMEDICA Share Price Swiss Exchange
Equities
OXB
GB0006648157
Biotechnology & Medical Research
Sales 2023 | 89.54M 112M 9.37B | Sales 2024 * | 131M 164M 13.66B | Capitalization | 328M 411M 34.34B |
---|---|---|---|---|---|
Net income 2023 | -157M -197M -16.43B | Net income 2024 * | -35M -43.91M -3.66B | EV / Sales 2023 | 2.38 x |
Net cash position 2023 * | 49.23M 61.75M 5.15B | Net cash position 2024 * | 13.8M 17.31M 1.44B | EV / Sales 2024 * | 2.41 x |
P/E ratio 2023 |
-1.35
x | P/E ratio 2024 * |
-9.59
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 80.81% |
Latest transcript on OXFORD BIOMEDICA
Managers | Title | Age | Since |
---|---|---|---|
Frank Mathias
CEO | Chief Executive Officer | 62 | 27/23/27 |
Stuart Paynter
DFI | Director of Finance/CFO | 52 | 29/17/29 |
Chairman | 68 | 24/20/24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Leone Patterson
BRD | Director/Board Member | 61 | 01/23/01 |
Chairman | 68 | 24/20/24 | |
Stuart Henderson
BRD | Director/Board Member | 66 | 01/16/01 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |